These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28314991)

  • 61. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association between genetic variants in the
    Hua RX; Zhuo ZJ; Zhu J; Jiang DH; Xue WQ; Zhang SD; Zhang JB; Li XZ; Zhang PF; Jia WH; Shen GP; He J
    Aging (Albany NY); 2016 Dec; 8(12):3311-3320. PubMed ID: 27929383
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Association of XPG rs17655G>C and XPF rs1799801T>C Polymorphisms with Susceptibility to Cutaneous Malignant Melanoma: Evidence from a Case-Control Study, Systematic Review and Meta-Analysis.
    Mohammadreza Niktabar S; Alireza Dastgheib S; Heiranizadeh N; Kargar S; Raee-Ezzabadi A; Jarahzadeh MH; Mohsen Miresmaeili S; Zare-Shehneh M; Neamatzadeh H
    Klin Onkol; 2020; 33(3):184-194. PubMed ID: 32683874
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Association between the XPG gene Asp1104His polymorphism and lung cancer risk.
    Zhou B; Hu XM; Wu GY
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323149
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An insight into clinical outcome of XPG polymorphisms in breast cancer.
    Malik SS; Mubarik S; Masood N; Khadim MT
    Mol Biol Rep; 2018 Dec; 45(6):2369-2375. PubMed ID: 30255276
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Genetic polymorphisms of the XPG and XPD nucleotide excision repair genes in sarcoma patients.
    Le Morvan V; Longy M; Bonaïti-Pellié C; Bui B; Houédé N; Coindre JM; Robert J; Pourquier P
    Int J Cancer; 2006 Oct; 119(7):1732-5. PubMed ID: 16646069
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations.
    He J; Qiu LX; Wang MY; Hua RX; Zhang RX; Yu HP; Wang YN; Sun MH; Zhou XY; Yang YJ; Wang JC; Jin L; Wei QY; Li J
    Hum Genet; 2012 Jul; 131(7):1235-44. PubMed ID: 22371296
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer.
    Geredeli C; Artac M; Yildirim S; Inal A; Dede I; Guler T; Boruban MC; Koral L; Karaagac M; Zamani AG; Altinok T; Aribas O; Bozcuk H; Demirkazik A
    Tumour Biol; 2015 Jun; 36(6):4279-85. PubMed ID: 25596702
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Polymorphisms of XPG/ERCC5 and risk of squamous cell carcinoma of the head and neck.
    Ma H; Yu H; Liu Z; Wang LE; Sturgis EM; Wei Q
    Pharmacogenet Genomics; 2012 Jan; 22(1):50-7. PubMed ID: 22108238
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacogenetic Association between
    Zhang N; Ouyang Y; Chang J; Liu P; Tian X; Yu J
    Biomed Res Int; 2020; 2020():3520764. PubMed ID: 33150172
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis.
    Tang N; Lyu D; Zhang Y; Liu H
    BMC Womens Health; 2017 Jun; 17(1):43. PubMed ID: 28623887
    [TBL] [Abstract][Full Text] [Related]  

  • 74. An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy.
    Zhang R; Jia M; Xu Y; Qian D; Wang M; Zhu M; Sun M; Chang J; Wei Q
    Int J Cancer; 2018 Mar; 142(6):1218-1229. PubMed ID: 29134637
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients.
    Powrózek T; Mlak R; Krawczyk P; Homa I; Ciesielka M; Kozioł P; Prendecka M; Milanowski J; Małecka-Massalska T
    Clin Transl Oncol; 2016 Feb; 18(2):125-31. PubMed ID: 26193985
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Association between the polymorphisms in XPG gene and gastric cancer susceptibility in Chinese populations: A PRISMA-compliant meta-analysis.
    Xia J; Sun R
    Medicine (Baltimore); 2017 Oct; 96(42):e8213. PubMed ID: 29049208
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Predictive impact of common variations in DNA repair genes on clinical outcome of osteosarcoma.
    Bai SB; Chen HX; Bao YX; Luo X; Zhong JJ
    Asian Pac J Cancer Prev; 2013; 14(6):3677-80. PubMed ID: 23886164
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.
    Wu J; Liu J; Zhou Y; Ying J; Zou H; Guo S; Wang L; Zhao N; Hu J; Lu D; Jin L; Li Q; Wang JC
    Clin Cancer Res; 2012 Jul; 18(14):3972-81. PubMed ID: 22705987
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
    Galván-Femenía I; Guindo M; Duran X; Calabuig-Fariñas S; Mercader JM; Ramirez JL; Rosell R; Torrents D; Carreras A; Kohno T; Jantus-Lewintre E; Camps C; Perucho M; Sumoy L; Yokota J; de Cid R
    Cancer Treat Res Commun; 2018; 15():21-31. PubMed ID: 30207284
    [TBL] [Abstract][Full Text] [Related]  

  • 80. ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.
    Cuffe S; Azad AK; Qiu X; Qiu X; Brhane Y; Kuang Q; Marsh S; Savas S; Chen Z; Cheng D; Leighl NB; Goss G; Laurie SA; Seymour L; Bradbury PA; Shepherd FA; Tsao MS; Chen BE; Xu W; Liu G
    Cancer Epidemiol; 2016 Apr; 41():50-6. PubMed ID: 26816351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.